Nabriva Therapeutics AG (NBRV) Earns Daily News Sentiment Rating of 0.13
News articles about Nabriva Therapeutics AG (NASDAQ:NBRV) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nabriva Therapeutics AG earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5949057650779 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Nabriva Therapeutics AG (NASDAQ NBRV) opened at 8.30 on Friday. The company’s market capitalization is $222.76 million. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $14.10. The company has a 50 day moving average of $8.48 and a 200 day moving average of $9.89.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. On average, analysts predict that Nabriva Therapeutics AG will post ($2.29) earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on NBRV shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target (up from $16.00) on shares of Nabriva Therapeutics AG in a research note on Monday, August 28th. SunTrust Banks, Inc. started coverage on shares of Nabriva Therapeutics AG in a research note on Friday, August 25th. They set a “buy” rating and a $20.00 price target for the company. Zacks Investment Research cut shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $21.00 price target (up from $13.00) on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Nabriva Therapeutics AG has a consensus rating of “Buy” and a consensus price target of $19.13.
COPYRIGHT VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/nabriva-therapeutics-ag-nbrv-earns-daily-news-sentiment-rating-of-0-13/1617081.html.
In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 69,854 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $10.51, for a total value of $734,165.54. Following the completion of the transaction, the insider now owns 2,490,952 shares in the company, valued at approximately $26,179,905.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of Nabriva Therapeutics AG stock in a transaction on Monday, September 18th. The stock was acquired at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 57,219 shares of company stock valued at $535,919 and have sold 252,845 shares valued at $2,585,694. Corporate insiders own 2.75% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.